Strattera斯德瑞

Strattera

atomoxetine

Manufacturer:

Eli Lilly

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Atomoxetine HCl
Indications/Uses
Treatment of ADHD in adults, adolescents & childn ≥6 yr.
Dosage/Direction for Use
Administer as single daily dose (morning) or in 2 divided doses (morning & late afternoon or early evening). Adult Initially a total daily dose of 40 mg maintained for a min of 7 days prior to upward dose titration according to clinical response & tolerability. Maintenance dose: 80-100 mg/day. Max dose: 100 mg/day. Adolescent & childn >70 kg Initially a total daily dose of 40 mg maintained for a min of 7 days prior to upward dose titration according to clinical response & tolerability. Maintenance dose: 80 mg/day. Max dose: 100 mg/day. Adolescent & childn up to 70 kg Initially at a total daily dose of 0.5 mg/kg maintained for a min of 7 days prior to upward dose titration according to clinical response & tolerability. Maintenance dose: 1.2 mg/kg/day.
Administration
May be taken with or without food: Swallow whole, do not open cap.
Contraindications
Hypersensitivity. Do not use w/in a min of 2 wk after discontinuing therapy w/ MAOI. Do not initiate MAOI treatment w/in 2 wk after discontinuing atomoxetine. Narrow-angle glaucoma. Symptomatic CV diseases, moderate to severe HTN, severe CV or cerebrovascular disorders. Pheochromocytoma.
Special Precautions
Suicide-related behavior. Patients w/ pre-existing structural cardiac abnormalities; congenital or acquired long QT or a family history of QT prolongation. Monitor heart rate & BP before & during treatment. Patients w/ additional risk factors for cerebrovascular conditions should be assessed at every visit for neurological signs & symptoms after initiating treatment. Discontinue in patients w/ jaundice or laboratory evidence of liver injury. Treatment emergent psychotic or manic symptoms. Monitor patients for appearance or worsening of aggressive behavior, hostility or emotional lability. Possible allergic events. Patients w/ history of seizure. Monitor growth & development in childn & adolescents during treatment. Monitor for appearance or worsening of anxiety symptoms, depressed mood & depression or tics. Priapism. Minor influence on the ability to drive & use machines. Pregnancy & lactation. Childn <6 yr. Elderly >65 yr.
Adverse Reactions
Decreased appetite, headache, nausea, increased BP & heart rate. Adult: Insomnia, dry mouth. Childn & adolescent: Somnolence, abdominal pain, vomiting.
Drug Interactions
Contraindicated w/ MAOIs. Increased exposure & Css w/ CYP2D6 inhibitors (eg, SSRIs, quinidine, terbinafine). Use w/ caution when combined w/ potent CYP450 inhibitors. Possible potentiation of CV effects w/ salbutamol or other β2 agonists. Potential increased risk of QT interval prolongation when administered w/ other QT prolonging drugs, drugs that cause electrolyte imbalance, CYP2D6 inhibitors. Use w/ caution when concomitantly used w/ medicinal drugs which are known to lower seizure threshold (eg, TCAs or SSRIs, neuroleptics, phenothiazines or butyrophenone, mefloquine, chloroquine, bupropion or tramadol). Decreased effectiveness of antihypertensive drugs. Increased BP w/ pressor agents or medications that may increase BP. Potential for additive or synergistic pharmacological effects w/ drugs that affect noradrenaline (eg, imipramine, venlafaxine, mirtazapine, pseudoephedrine, phenylephrine).
MIMS Class
Other CNS Drugs & Agents for ADHD
ATC Classification
N06BA09 - atomoxetine ; Belongs to the class of centrally-acting sympathomimetics. Used as CNS stimulant.
Presentation/Packing
Form
Strattera cap 10 mg
Packing/Price
28's
Form
Strattera cap 18 mg
Packing/Price
28's
Form
Strattera cap 25 mg
Packing/Price
28's
Form
Strattera cap 40 mg
Packing/Price
28's
Form
Strattera cap 60 mg
Packing/Price
28's
Form
Strattera cap 80 mg
Packing/Price
28's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in